ArticleArchives of dermatological research2025
Effects of biological agents on lipid profile and hemogram parameters in patients with psoriasis.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biologic therapy in geriatric psoriasis: 6-month real-world data on PASI, inflammatory indices, and hepatitis B/tuberculosis safety.Biomolecules & biomedicine · 2026Article
- The Dynamics of Blood-Count-Derived Inflammatory Indices in the Course of Systemic Treatment for Psoriasis: A Single Center Study.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of biological agents on laboratory parameters in patients with psoriasis remain incompletely characterized, with conflicting data reported. To investigate the effects of five biological agents on lipid profiles, hemogram parameters, inflammatory markers, and their correlation with disease activity in psoriasis patients. This retrospective study analyzed hemogram parameters (n = 153) and lipid profiles (n = 124) in psoriasis patients treated with adalimumab, etanercept, infliximab, ustekinumab, or secukinumab for ≥ 6 months. Parameters were evaluated at baseline, week 12, and week 24. Patients with conditions potentially affecting these parameters were excluded. Platelet counts decreased significantly in etanercept and secukinumab groups (p < 0.001, p < 0.05) and all patients (p < 0.001). Lymphocyte counts increased in adalimumab and etanercept groups (p < 0.001, p < 0.01) and all patients (p < 0.001). Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio decreased significantly in adalimumab, etanercept, secukinumab groups (p < 0.05). Triglyceride levels increased in the ustekinumab group (10.91%) and all patients (3.2%) (p < 0.05). Total cholesterol, LDL, HDL, and atherogenic index showed no significant changes. A strong positive correlation was found between neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio changes (r = 0.646, p < 0.001). Biological agents have specific effects on hematological and lipid parameters in psoriasis patients. The observed changes in inflammatory markers and triglycerides suggest the importance of laboratory monitoring during biological therapy.
Indexed as
Identifiers
40208364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.